Market Overview

The Week Ahead In Biotech: Avadel, Epizyme In Focus In A Quiet Week

Share:
The Week Ahead In Biotech: Avadel, Epizyme In Focus In A Quiet Week

Biotech stocks were seen consolidating last week after advancing in the previous week. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) reached a 52-week high of 121.16 Monday, although it has come off this level since then.

The week saw huge moves in reaction to presentations at the American Society of Hematology annual meeting. A few M&A announcements were made, including Merck & Co., Inc.'s (NYSE: MRKdeal to buy ArQule, Inc. (NASDAQ: ARQL) and Sanofi SA's (NASDAQ: SNY) proposed purchase of Synthorx Inc (NASDAQ: THOR).

Correvio Pharma Corp (NASDAQ: CORV) fell sharply in the week following an FDA panel snub of its atrial fibrillation treatment Brinavess.

The following are key catalytic events expected in the week ahead: 

PDUFA Date

The FDA is set to rule on Avadel Pharmaceuticals PLC's (NASDAQ: AVDL) NDA for AV001, a sterile injectable product for the hospital market. The PDUFA date is scheduled for Sunday following a three-month extension from the original decision date of Sept. 15.

Adcom Meeting

FDA's Oncologic Drugs Advisory Committee will discuss Wednesday Epizyme Inc's (NASDAQ: EPZM) NDA for tazemetostat tablets for treating patients with metastatic or locally advanced epithelioid sarcoma who are not eligible for curative surgery.

Earnings

Anavex Life Sciences Corp (NASDAQ: AVXL) (Monday, after the market close)

The week could see clinical readouts from companies that have given a timeline of December/fourth quarter/second half of 2019/year-end 2019.

Related Links:

Regeneron Shares Swing On Sanofi's Hint At Sale Of Ownership Stake, Amendments To Drug Collaborations

Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates

Posted-In: Biotech News Previews FDA Trading Ideas General Best of Benzinga

 

Related Articles (ARQL + AVDL)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com